Raphael M. Bonelli
Research Subjects
Raphael M. Bonelli has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Gerald Niederwieser
Department of Neurology and Psychiatry, Hospital BHB Eggenberg, Bergstrasse 27, A‐8021 Graz, Austria
5 shared publicationsFranz Reisecker
3 shared publicationsG. Niederwieser
Department of Neurology and Psychiatry, Hospital BHB Eggenberg, Bergstrasse, Graz, Austria
2 shared publicationsP. Költringer
Department of Neurology and Psychiatry, Hospital BHB Eggenberg, Bergstrasse, Graz, Austria
2 shared publicationsPeter Költringer
Department of Neurology & Psychiatry, Hospital BHB Eggenberg, Bergstrasse, Graz, Austria
2 shared publicationsA. Gruber
1 shared publication
Latest Publications
- 1 May 2004
- Vol. 31 (2) , 56-7
Transient hypoglycemic abducens palsy.
Since 1928, among the thousands of patients treated for insulinoma, only 32 cases with peripheral neuropathy have been reported. None of these described an affection of the cranial nerves. We present a 56 old woman, who suffered from chronic hyperinsulinism due to an insulinoma. For ten years, the patient has developed progressively marked hypoglycemic attacks of up to 20 mg/dl. Recently we have observed the development of a paresis of the right abducens nerve lasting for 6 weeks.
- 1 May 2004
- Vol. 31 (2) , 56-7
Transient hypoglycemic abducens palsy.
Since 1928, among the thousands of patients treated for insulinoma, only 32 cases with peripheral neuropathy have been reported. None of these described an affection of the cranial nerves. We present a 56 old woman, who suffered from chronic hyperinsulinism due to an insulinoma. For ten years, the patient has developed progressively marked hypoglycemic attacks of up to 20 mg/dl. Recently we have observed the development of a paresis of the right abducens nerve lasting for 6 weeks.
- 11 March 2003
- Published by Wolters Kluwer Health in Neurology
- Vol. 60 (5) , 883-884
Minocycline for Huntington’s disease: An open label study
- 11 March 2003
- Published by Wolters Kluwer Health in Neurology
- Vol. 60 (5) , 883-884
Minocycline for Huntington’s disease: An open label study
- 17 January 2003
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 18 (3) , 227-229
Zotepine in Huntington's disease
The authors report a patient with Huntington's disease (HD) presenting with severe chorea. The motor scale of the unified HD rating scale (UHDRS‐I) revealed 81 points. Motor function clearly improved with zotepine, until she reached an UHDRS‐I of 34 points on day 7 of treatment. The patient was stable for at least 12 weeks. The improvement includes all seven categories of the UHDRS‐I, especially chorea, gait and oral function. This is the first description of zotepine in HD. Our findings suggest that zotepine is useful in the treatment of HD chorea. Controlled trials of its use in HD would be welcome. Copyright © 2003 John Wiley & Sons, Ltd.
- 17 January 2003
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 18 (3) , 227-229
Zotepine in Huntington's disease
The authors report a patient with Huntington's disease (HD) presenting with severe chorea. The motor scale of the unified HD rating scale (UHDRS‐I) revealed 81 points. Motor function clearly improved with zotepine, until she reached an UHDRS‐I of 34 points on day 7 of treatment. The patient was stable for at least 12 weeks. The improvement includes all seven categories of the UHDRS‐I, especially chorea, gait and oral function. This is the first description of zotepine in HD. Our findings suggest that zotepine is useful in the treatment of HD chorea. Controlled trials of its use in HD would be welcome. Copyright © 2003 John Wiley & Sons, Ltd.
- 1 November 2002
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 203-204, 207-209
Cerebrospinal fluid tissue transglutaminase in vascular dementia
- 1 November 2002
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 203-204, 207-209
Cerebrospinal fluid tissue transglutaminase in vascular dementia
- 1 October 2002
- Published by Elsevier in Neurobiology of Disease
- Vol. 11 (1) , 106-110
Cerebrospinal Fluid Tissue Transglutaminase as a Biochemical Marker for Alzheimer's Disease
- 1 October 2002
- Published by Elsevier in Neurobiology of Disease
- Vol. 11 (1) , 106-110
Cerebrospinal Fluid Tissue Transglutaminase as a Biochemical Marker for Alzheimer's Disease
- 1 September 2002
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 25 (5) , 263-265
Olanzapine for Huntington's Disease: An Open Label Study
The aim of this prospective open label study was to assess the efficacy of olanzapine for motor symptoms in Huntington's disease (HD). Olanzapine was administrated to nine patients with genetically confirmed HD in increasing doses until satisfactory clinical effect or the appearance of side effects. The patients were evaluated at baseline and after 14 days of treatment using the motor scale of the Unified HD Rating Scale (UHDRS). The patients improved significantly in most subscores of the UHDRS, including fine motor tasks, although some patients needed a rather high dose (30 mg per day). No adverse effects were reported by the patents spontaneously or were observed directly by the investigator. High-dose olanzapine seems to be useful in choreatic HD patients. A double blind, placebo-controlled trial appears warranted to definitively establish the symptomatic value of olanzapine in HD.
- 1 September 2002
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 25 (5) , 263-265
Olanzapine for Huntington's Disease: An Open Label Study
The aim of this prospective open label study was to assess the efficacy of olanzapine for motor symptoms in Huntington's disease (HD). Olanzapine was administrated to nine patients with genetically confirmed HD in increasing doses until satisfactory clinical effect or the appearance of side effects. The patients were evaluated at baseline and after 14 days of treatment using the motor scale of the Unified HD Rating Scale (UHDRS). The patients improved significantly in most subscores of the UHDRS, including fine motor tasks, although some patients needed a rather high dose (30 mg per day). No adverse effects were reported by the patents spontaneously or were observed directly by the investigator. High-dose olanzapine seems to be useful in choreatic HD patients. A double blind, placebo-controlled trial appears warranted to definitively establish the symptomatic value of olanzapine in HD.
- 1 July 2002
- Published by Springer Nature in Journal of Neurology
- Vol. 249 (8) , 1114-1115
Quetiapine in Huntington's disease: a first case report
- 1 July 2002
- Published by Springer Nature in Journal of Neurology
- Vol. 249 (8) , 1114-1115
Quetiapine in Huntington's disease: a first case report
- 7 March 2002
- Published by Wiley in European Journal of Neurology
- Vol. 9 (2) , 183-184
Riluzole and olanzapine in Huntington's disease
- 7 March 2002
- Published by Wiley in European Journal of Neurology
- Vol. 9 (2) , 183-184
Riluzole and olanzapine in Huntington's disease
- 7 March 2002
- Published by Wiley in European Journal of Neurology
- Vol. 9 (2) , 184-185
Zolpidem in progressive supranuclear palsy
- 7 March 2002
- Published by Wiley in European Journal of Neurology
- Vol. 9 (2) , 184-185
Zolpidem in progressive supranuclear palsy
- 1 March 2002
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 17 (2) , 91-3
High-dose olanzapine in Huntington??s disease
The few reports available on olanzapine in Huntington's disease (HD) are insufficiently documented and/or insufficiently dosed. We describe a 30-year-old woman with genetically confirmed HD who presented with severe chorea. She was not able to eat or dress without help and did not respond to haloperidol; the motor scale of the Unified HD Rating Scale (UHDRS-I) revealed 65 of a possible 124 points. After admission, we treated the patient with a high dose of olanzapine (30 mg daily). The chorea almost ceased in the next 2 days, she was able to eat and walk without assistance (UHDRS-I of 21 points), and fine motor tasks improved, as well as gait and eye movements. This effect lasted for 5 months. We conclude that high-dose olanzapine appears to be useful in grave choreatic attacks.
- 1 March 2002
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 17 (2) , 91-3
High-dose olanzapine in Huntington??s disease
The few reports available on olanzapine in Huntington's disease (HD) are insufficiently documented and/or insufficiently dosed. We describe a 30-year-old woman with genetically confirmed HD who presented with severe chorea. She was not able to eat or dress without help and did not respond to haloperidol; the motor scale of the Unified HD Rating Scale (UHDRS-I) revealed 65 of a possible 124 points. After admission, we treated the patient with a high dose of olanzapine (30 mg daily). The chorea almost ceased in the next 2 days, she was able to eat and walk without assistance (UHDRS-I of 21 points), and fine motor tasks improved, as well as gait and eye movements. This effect lasted for 5 months. We conclude that high-dose olanzapine appears to be useful in grave choreatic attacks.